Fig. 3: Comparison of therapeutic efficacies by CATP with VEE, SIN, and SFV4 capsids/envelop.
From: Cascade amplification of therapeutic payloads for cancer immunotherapy
Six- to eight-week-old C57BL/6 mice (n = 5 per group, a cage of animal) were subcutaneously inoculated with 1 million B16F10 melanoma cells. Seven days post-inoculation, mice were intratumorally treated with PBS (Control group of basal line), or LNP encapsulated 10 µg of SamRNA encoding mIL-12 and 1 µg modified mRNA encoding capsids/envelops from VEE (Control group of treated group), SIN, and SFV4 as indicated. Results are shown as: Tumor areas (Y-axis), Survival rates (Y-axis), and Body weight changes (Y-axis) versus days post-B16F10 cell inoculation (X-axis) (a, b, c), respectively. d Illustrations of CATP with oncolytic effects by the capsids/envelop such as SFV4 was created in BioRender. Li, Y. (2025) https://BioRender.com/bguaszo. The SamRNA, regular mRNA, therapeutic payloads, capsids/envelop, defective viruses, tumor associated antigens (TAA), and inflammasomes triggered by defective viruses and LNP-mRNA are indicated. The P-Values labeled in a and c were determined by a two-way ANOVA test and Comparison of Survival Curves (Kaper-myer) test.
